Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco

Cancer

Volumn 73, Issue 10, 1994, Pages 2570-2582

  Ling, Stella M ^a   Iii, Mack Roach ^a   Larson, David A ^a   Wara, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acquired immune deficiency syndrome; brain; cancer; central nervous system; human immunodeficiency virus; immunosuppression; lymphoma

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; HUMAN; LYMPHOMA; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0028362941     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19940515)73:10<2570::AID-CNCR2820731019>3.0.CO;2-1     Document Type: Article

References (99)

1. Primary central nervous system lymphoma
2. Primary malignant lymphomas of the central nervous system in man
3. Primary malignant lymphoma of the central nervous system
4. Central nervous system lymphoma
5. Primary malignant lymphoma of the central nervous system
6. Primary malignant lymphomas of the central nervous system
7. Primary lymphoma of the central nervous system: patterns of failure and factors that influence survival
8. Primary lymphoma of the central nervous system
9. Development of non–Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long–term antiretroviral therapy
10. Projections of the number of persons diagnosed with AIDS and the number of immunosuppressed HIV–infected per–sons–United States, 1992–1994
11. AIDS related lymphoma
12. HIV–associated non–Hodgkin's lymphomas
13. HIV–related malignancies
14. AIDS‐related malignant lymphoma: results of prospective treatment trials
15. Cerebral lymphoma in AIDS: clinical, radiological, neurological and immunopathological study
16. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS)
17. Lymphoma related to human immunodeficiency virus: the epidemic shifts
18. AIDS‐related lymphoma neoplasia
19. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathological study
20. ‘Biologic’ differences in acquired immune deficiency syndrome‐associated non‐Hodgkin's lymphomas?
21. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome
22. Primary central nervous system lymphoma in AIDS
23. Neuroepidemiology of acquired immunodeficiency syndrome
24. Primary central nervous system lymphomas in patients with AIDS
25. Epstein‐Barr virus in AIDS‐related primary central nervous system lymphoma
26. Clinical manifestations and treatment of HIV‐related non‐Hodgkin lymphoma
27. The therapy of primary brain lymphoma
28. The presence of nitrogen mustards in the palliative treatment of cancer
29. The Karnofsky performance status scale
30. Regression models and life tables
31. Nonparametric estimation from incomplete observation
32. Increasing incidence of primary brain lymphoma in the US
33. Cancer trends in a population at risk of acquired immunodeficiency syndrome
34. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome
35. AIDS‐related non‐Hodgkin's lymphoma in San Francisco
36. Second malignant neoplasms associated with immuno‐suppressive medications
37. Risk of cancer in renal transplant recipients
38. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein‐Barr virus
39. Malignant lymphomas in a population at risk for acquired immune deficiency syndrome
40. Malignant lymphomas in patients with or at risk for AIDS in Italy
41. Lymphadenopathy in renal transplant patients treated with immunosuppressive antibodies (OKT3 and antithymocyte globulin)
42. Malignant lymphomas in patients with HIV infection in Italy
43. AIDS‐associated non‐Hodgkin's lymphoma in Italy: intravenous drug users versus homosexual men
44. Acquired immunodeficiency virus infection
45. Survival trends for patients with AIDS
46. The immunopathogenesis of human immunodeficiency virus infection
47. Opportunistic non‐Hodgkin's lymphomas among severely immunocompromised HIV‐infected patients surviving for prolonged periods on antiretroviral therapy
48. HIV‐associated malignancies
49. Primary central nervous system lymphomas in patients with AIDS
50. Primary lymphoma of the central nervous system
51. Outcome of primary central nervous system lymphoma: a study of 32 patients
52. Primary central nervous system lymphoma: analysis of prognostic variables and patterns of treatment failure
53. Non‐Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group
54. Primary central nervous system lymphoma: long‐term survival following treatment with radiation and methotrexate
55. Malignant lymphomas in HIV‐seropositive patients: frequency, features and prognosis: report on 31 cases
56. Incidence and clinicopathological heterogeneity of HIV‐related non‐Hodgkin's lymphoma
57. Lymphoma in acquired immunodeficiency syndrome
58. Primary lymphoma of the central nervous system
59. Lymphoma in the immunocompromised patient
60. Central nervous system lymphoma: histologic types and CT appearance
61. Primary malignant lymphoma of the brain
62. The prognostic importance of CT features in primary intracranial lymphoma
63. Studies of primary central nervous system lymphoma with fluorine‐18‐fluorodeoxyglucose positron emission tomography
64. Radiation therapy in the management of primary malignant lymphoma of the brain
65. Central nervous system involvement in non‐Hodgkin's lymphoma: an analysis of 105 cases
66. The role of bone marrow transplantation in the non‐Hodgkin's lymphomas
67. Improved survival rate in primary intracranial lymphoma treated by high‐dose radiation and systemic vincristine‐doxorubicin‐cyclophosphamide‐prednisolone chemotherapy
68. Primary central nervous system lymphoma: a new clinical challenge
69. Combined modality therapy for primary CNS lymphoma
70. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy
71. Primary CNS lymphoma treated with osmotic blood‐brain barrier disruption: prolonged survival and preservation of cognitive function
72. Primary lymphoma of the central nervous system
73. High‐dose methotrexate for non‐AIDS primary central nervous system lymphoma
74. Primary central nervous system lymphoma
75. Primary central nervous system lymphoma in acquired immune deficiency syndrome
76. Projections of the incidence of non‐Hodgkin's lymphoma related to acquired immunodeficiency syndrome
77. Acquired immunodeficiency syndrome‐associated lymphomas
78. Specific translocations characterize Burkitt's‐like lymphoma of homosexual men with the acquired immunodeficiency syndrome
79. Small noncleaved B cell Burkitt‐like lymphoma with chromosome t(8; 14) translocation and Epstein‐Barr virus nuclear‐associated antigen in a homosexual man with acquired immune deficiency syndrome
80. Detection of Epstein‐Barr virus genomes in AIDS related lymphomas: sensitivity and specificity of in situ hybridisation compared with Southern blotting
81. AIDS‐related lymphoma: histopathology, immunophenotype, and association with Epstein‐Barr virus as demonstrated by in situ nucleic acid hybridization
82. Different Epstein‐Barr virus expression in lymphomas from immunocompromised and immunocompetent patients
83. Aggressive non‐Hodgkin's lymphomas in immunocompromised homosexual males
84. Variable morphology of human immuno‐deficiency virus‐associated lymphomas with C‐MYC rearrangements
85. Molecular and immunophenotypic characterization of AIDS‐associated, Epstein‐Barr virus‐negative, polyclonal lymphoma
86. Documentation of Epstein‐Barr virus infection in immunodeficient patients with life‐threatening lymphoproliferative diseases by clinical, virological and immunopathological studies
87. Evidence for molecular subtypes of HIV‐associated lymphoma: division into peripheral monoclonal lymphoma, peripheral polyclonal lymphoma, and central nervous system lymphoma
88. Definition of two distinct types of AIDS‐associated non‐Hodgkin lymphoma
89. Expression of LFA‐1/ICAM‐1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain
90. Central nervous involvement in patients with diffuse aggressive non‐Hodgkin's lymphoma
91. Management of HIV infection: a summary of summaries (I)
92. Primary central nervous system lymphoma related to Epstein‐Barr virus in a patient with acquired immune deficiency syndrome
93. In situ demonstration of Epstein‐Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome‐related lymphomas: correlation with tumor morphology and primary site
94. Acquired immunodeficiency syndrome and non‐Hodgkin's lymphomas
95. The neuropathology of AIDS
96. Histopathologic features of high‐grade non‐Hodgkin's lymphomas in acquired immunodeficiency syndrome
97. Central nervous system lymphoma in the acquired immunodeficiency syndrome